Abstract: An axillary support device is provided for decompressing the axilla (armpit) and associated structures in a sidelying position. A thoracic cushion provides firm axillary support to a user at the level of the mid to upper thorax, distal to the axilla. A head cushion connected to the thoracic cushion supports the user's head and may maintain a neutral cervical spine alignment position. A connector connecting the cushions creates a valley to receive an upper arm of the user. A back support may be used to maintain the sidelying position. An inflatable bladder may be used to adjust the axillary support device in order to appropriately relieve pressure on the user's axilla and associated structures. With the axillary support device, the upper arm of the user is relatively free to extend perpendicularly in front of the body in the sidelying position with reduced stress on the lateral shoulder and axilla.

Abstract: Encryption of Internet Protocol (IP) traffic using IP Security (IPSec) at the edge of the enterprise network, in such a way as to support resilient BGP/MPLS IP VPN network designs. The IP traffic is securely tunneled within IPSec tunnels from the edge to the edge of the enterprise network. The IPSec traffic is also tunneled within MPLS tunnels from the edge to the edge of the service provider network. The enterprise network thus manages its own IPSec site-to-site VPN. The service provider thus independently manages its own MPLS network. The result provides an IP VPN or Layer 3 MPLS VPN to the enterprise; the enterprise IPSec network can thus be considered as an overlay to the MPLS service provider network.

Abstract: The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of the present invention. In another aspect the present invention relates to methods for producing the aforementioned compositions.

Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.

Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.

Abstract: A region of air is manipulated to reflect, absorb, or redirect sound energy to prevent the sound energy from reaching a listener separated from the sound source by the region of air. The region of air may be manipulated by directing ultrasonic sound waves with a sound pressure level of at least 140 decibels at the region of air.

Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.

Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.

Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

Abstract: The invention relates to the use of Fused Deposition Modeling to construct three-dimensional (3D) bioresorbable scaffolds from bioresorbable polymers such as polycaprolactone (PCL), or from composites of bioresorbable polymers and ceramics, such as polycaprolactone/hydroxyapatite (PCL/HA). Incorporation of a bioresorbable ceramic to produce a hybrid/composite material support provides the desired degradation and resorption kinetics. Such a composite material improves the biocompatibility and hard tissue integration and allows for increased initial flash spread of serum proteins. The basic resorption products of the composite also avoids the formation of an unfavorable environment for hard tissue cells due to a decreased pH. The scaffolds have applications in tissue engineering, e.g., in tissue engineering bone and cartilage.

Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.

Abstract: Disclosed herein are apparatus and methods for isolating a fraction of interest from a physiological fluid sample. A sample holder for isolating a fraction of interest from a physiological fluid sample includes a flexible compartment and a rigid exoskeleton that supports the flexible compartment. The flexible compartment may have at least one reservoir with a height to volume ratio of about 0.1 cm/mL to about 5 cm/mL. An automated device for extracting a fraction of interest from the sample includes a sample holder with a flexible compartment supported by a rigid exoskeleton, a support for the sample holder connected to one or more fluid extraction devices, and a motor for moving the extraction device relative to the sample holder. The automated device may include an optical sensor and may include a clamp for clamping the flexible compartment.

Abstract: The present invention addresses the problem of providing illumination in a manner that is energy efficient and intelligent. In particular, the present invention uses distributed processing across a network of illuminators to control the illumination for a given environment. The network controls the illumination level and pattern in response to light, sound, and motion. The network may also be trained according to uploaded software behavior modules, and subsets of the network may be organized into groups for illumination control and maintenance reporting.

Abstract: A method of mounting a lock to a pick-up truck tailgate latching mechanism including the steps of locating targets for holes to be formed in a plastic bezel, the bezel carrying a handle for the tailgate, forming the holes in the plastic bezel, and securing the locking mechanism to the bezel via the formed holes.

Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.

Abstract: A liquid crystal structure (200) comprising first and second reflective regions (214a, 214b, 214c) arranged to reflect respective first and second colours. The first and second reflective regions (214a, 214b, 214c) are disposed transversely to the direction of reflection (R). Each region includes a reflective back area and a selector (210) controllable to control light reflected from the region. Furthermore, a controllable reflector (212) is superposed over the reflective region in the direction of reflection (R) and controllable to transmit or scatter incident light.

Abstract: A bacteria deactivation device that has a porous medium through which water and bacteria contained in the water, like E. coli and fecal coliform, are passed. Colloidal silver within the medium deactivates bacteria that pass therethrough. The medium has a porosity up to 80% and pores sized to provide flow rates up to 8 liters per hour while meeting Environmental Protection Agency limits for human consumption of silver.

Abstract: A method of managing faults in a ring network may include configuring a ring network to be in a “horseshoe” topology by disabling a communications link from distributing media between a selected pair of adjacent nodes while allowing other communications or non-related media to continue to be distributed via the adjacent nodes. In the event of a failure, the disabled communications path may be re-enabled, and first or second backup communications paths may be employed, where the first backup communications path may use primary connections between adjacent nodes used for primary communications paths normally used to carry the media, and the second backup communications paths may use secondary connections between non-adjacent nodes. The disabled communications path may be dynamically moved in a logical or physical manner in an event of a communications link or node failure to maintain a “horseshoe” topology in the ring network.

Abstract: The present invention provides a business facilitation system enabling retail investors to acquire equity in business entities that are seeking equity financing. The fund seeker electronically posts a proposal seeking funds. Through electronic communication means investors commit to buying the private equity at the rate fixed or indicate interest in getting due diligence conducted. If the funds sought are not met by unconditional commitments then investors who had indicated interest in due diligence can make conditional commitments based on the results of the due diligence for which they are willing to pool in funds. If a certain percentage of the funds sought are committed or met though conditional commitments whose conditions are satisfied within a fixed time period, then the fund seeker honors the proposal. Otherwise the fund seeker can revise, extend, honor or withdraw the proposal.